Gentium S.p.A. (NASDAQ:GENT): Closing price $31.81
On Tuesday, Gentium reported that the European Commission has granted a Marketing Authorization for Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy. Defitelio is the first okayed treatment in the European Union for this life-threatening condition. The authorization represents the formal endorsement of the positive opinion received from the European Medicine Agency’s Committee for Human Medicinal Product on July 26, 2013. Gentium intends to commence commercialization of Defitelio in the European Union in December.